(E)-2-(2-nitrobenzylidene)-N-methylhydrazinecarbothioamide | 51146-59-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-2-(2-nitrobenzylidene)-N-methylhydrazinecarbothioamide
• 英文别名: (E)-N-methyl-2-(2-nitrobenzylidene)hydrazinecarbothioamide；2-nitro-benzaldehyde-(4-methyl thiosemicarbazone)；2-Nitro-benzaldehyd-(4-methyl-thiosemicarbazon)；1-methyl-3-[(E)-(2-nitrophenyl)methyleneamino]thiourea；1-methyl-3-[(E)-(2-nitrophenyl)methylideneamino]thiourea
• CAS: 51146-59-9
• 化学式: C₉H₁₀N₄O₂S
• 分子量: 238.27
• InChiKey: HDWYUWITXRUKAT-IZZDOVSWSA-N

物化性质

• 熔点：
  234-235 °C
• 沸点：
  380.5±44.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [ruthenium(II)(hydride)(chloride)(carbonyl)(triphenylarsine)3] 、 (E)-2-(2-nitrobenzylidene)-N-methylhydrazinecarbothioamide 在 三乙胺 作用下， 以 甲醇 、 苯 为溶剂， 反应 8.0h， 以56%的产率得到
  参考文献：
  名称：

  DNA binding, DNA cleavage, antioxidant and cytotoxicity studies on ruthenium(II) complexes of benzaldehyde 4-methyl-3-thiosemicarbazones

  摘要：

  Four new ruthenium(II) complexes with N(4)-methyl thiosemicarbazone ligands, (E)-2-(2-chlorobenzylidene)-N-methylhydrazinecarbothioamide (HL1) and (E)-N-methyl-2-(2-nitrobenzylidene)hydrazinecarbothioamide (HL2), were prepared and fully characterized by various spectro-analytical techniques. The Schiff bases act as bidentate, monobasic chelating ligands with S and N as the donor sites and are preferably found in the thiol form in all the complexes studied. The molecular structure of HL1 and HL2 were determined by single crystal X-ray diffraction method. DNA binding of the compounds was investigated by absorption spectroscopy which indicated that the complexes bind to DNA via intercalation. The oxidative cleavage of the complexes with CT-DNA inferred that the effects of cleavage are dose dependent. Antioxidant studies of the ligands and complexes showed the significant antioxidant activity against DPPH radical. In addition, the in vitro cytotoxicity of the ligands and complexes against MCF-7 cell line was assayed which showed higher cytotoxic activity with the lower IC50 values indicating their efficiency in killing the cancer cells even at low concentrations. (C) 2012 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.saa.2012.12.064
• 作为产物：
  描述：

  4-甲基氨基硫脲 、 邻硝基苯甲醛 生成 (E)-2-(2-nitrobenzylidene)-N-methylhydrazinecarbothioamide
  参考文献：
  名称：

  DE845344

  摘要：

  公开号：

文献信息

• NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS
  申请人：Shenyang Pharmaceutical University

  公开号：US20150307453A1

  公开（公告）日：2015-10-29

  The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R 1 , R 2 , X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

  该发明涉及一系列喹啉衍生物，其一般式为I，包括药学上可接受的盐、水合物、溶剂合物或前药。其中M、R1、R2、X、Y和n的定义如索取权所述。一般式I的化合物显示出对c-Met激酶的强效抑制活性。本发明还涉及这些化合物、药学上可接受的盐和水合物的用途，用于制备用于治疗和/或预防由c-Met激酶异常表达引起的疾病的药物，特别是用于治疗和/或预防癌症。
• NOVEL QUINOLINE COMPOUND AND USE THEREOF
  申请人：Shenyang Pharmaceutical University

  公开号：EP2915806A1

  公开（公告）日：2015-09-09

  The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

  本发明涉及一系列通式 I 的喹啉衍生物、药学上可接受的盐、水合物、溶液或原药。其中 M、R1、R2、X、Y 和 n 的定义如权利要求所述。通式 I 的化合物对 c-Met 激酶具有强效抑制活性。本发明进一步涉及这些化合物、药学上可接受的盐和水合物用于制备治疗和/或预防由 c-Met 激酶异常表达引起的疾病的药物，特别是用于治疗和/或预防癌症。
• Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity
  作者：Rômulo P. Tenório、Cristiane S. Carvalho、Carla S. Pessanha、José G. de Lima、Antônio R. de Faria、Antônio J. Alves、Edésio J.T. de Melo、Alexandre J.S. Góes

  DOI：10.1016/j.bmcl.2005.03.048

  日期：2005.5

  Thiosemicarbazone and 4-thiazolidinone derivatives were synthesized in one and two step, respectively, from thiosemicarbazide, in satisfactory yields. Then, the synthesized compounds were submitted to evaluation against host cells infected with Toxoplasma gondii. The present studies showed that thiosemicarbazones 2 and 4-thiazolidinone derivatives 3 were effective against intracellular T. gondii. (c) 2005 Elsevier Ltd. All rights reserved.
• Mixed ligand ruthenium(III) complexes of benzaldehyde 4-methyl-3-thiosemicarbazones with triphenylphosphine/triphenylarsine co-ligands: Synthesis, DNA binding, DNA cleavage, antioxidative and cytotoxic activity
  作者：K. Sampath、S. Sathiyaraj、G. Raja、C. Jayabalakrishnan

  DOI：10.1016/j.molstruc.2013.04.051

  日期：2013.8

  The new ruthenium(III) complexes with 4-methyl-3-thiosemicarbazone ligands, (E)-2-(2-chlorobenzylidene)-N-methylhydrazinecarbothioamide (HL1) and (E)-2-(2-nitrobenzylidene)-N-methylhydrazinecarbothioamide (HL2), were prepared and characterized by various physico-chemical and spectroscopic methods. The title compounds act as bidentate, monobasic chelating ligands with S and N as the donor sites and are preferably found in the thiol form in all the complexes studied. The molecular structure of HL1 and HL2 were determined by single crystal X-ray diffraction method. DNA binding of the ligands and complexes were investigated by absorption spectroscopy and IR spectroscopy. It reveals that the compounds bind to nitrogenous bases of DNA via intercalation. The oxidative cleavage of the complexes with CT-DNA inferred that the effects of cleavage are dose dependent. Antioxidant study of the ligands and complexes showed the significant antioxidant activity against DPPH radical. In addition, the in vitro cytotoxicity of the ligands and complexes against MCF-7 cell line was assayed which showed higher cytotoxic activity with the lower IC50 values indicating their efficiency in killing the cancer cells even at low concentrations. (c) 2013 Elsevier B.V. All rights reserved.
• US9783499B2
  申请人：——

  公开号：US9783499B2

  公开（公告）日：2017-10-10